Sera Prognostics, Inc. ( (SERA) ) has released its Q3 earnings. Here is a breakdown of the information Sera Prognostics, Inc. presented to its investors.
Sera Prognostics, Inc. is a health diagnostics company focused on advancing maternal and neonatal health through innovative pregnancy biomarker information, providing early detection and proactive intervention strategies to improve outcomes for mothers and newborns. In its third-quarter 2024 earnings report, Sera Prognostics highlighted several strategic initiatives including the active pursuit of publishing its PRIME study results and launching a consumer-initiated channel for its PreTRM® testing, which is expected to enhance market reach. The company reported third-quarter revenue of $29,000, down from $42,000 in the same period last year, with operating expenses rising to $8.9 million due to strategic investments. Despite a net loss of $7.9 million, Sera continued its focus on product development and commercialization efforts, including a strengthened commercial team and improved laboratory capacity from a transition to ambient whole blood collection. Moving forward, Sera Prognostics anticipates that its ongoing awareness campaigns and strategic initiatives will position the company for a commercial breakthrough in the maternal care market, aiming for improved profitability and revenue growth.
